Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas

References

• Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–947.
   PubMed Web of Science ®Google Scholar
• Hnisz D, Weintraub AS, Day DS, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 2016;351(6280):1454–1458.
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Young RA, Sharp PA. Super-enhancer-mediated RNA processing revealed by integrative microRNA network analysis. Cell. 2017;168(6): 1000–1014. e15.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Boutselakis H, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45(D1):D777–D783.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Boutselakis H, et al. COSMIC: high-resolution cancer genetics using the catalogue of somatic mutations in cancer. Curr Protoc Hum Genet. 2016;91. DOI: 10.11.1-10.11.37.
   PubMedGoogle Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558.
   PubMed Web of Science ®Google Scholar
• Eiring AM, Page BDG, Kraft IL, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2015;29(3):586–597.
   PubMed Web of Science ®Google Scholar
• Danis E, Yamauchi T, Echanique K, et al. Ezh2 controls an early hematopoietic program and growth and survival signaling in early T cell precursor acute lymphoblastic leukemia. Cell Rep. 2016;14(8):1953–1965.
   PubMed Web of Science ®Google Scholar
• Baker SG. A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst. 2015;107(2):1-8.
   Google Scholar
• Rosenfeld S. Biomolecular self-defense and futility of high-specificity therapeutic targeting. Gene Regul Syst Bio. 2011;5:89–104.
   PubMedGoogle Scholar
• Jing T, Tero A. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des. 2014;20(1):23–36.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Verstovsek S, Manshouri T, et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther. 2013;12:577–588.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Tevet M, Trifa A, et al. 2016 WHO clinical molecular and pathological criteria for classification and staging of myeloproliferative neoplasms (MPN) caused by MPN driver mutations in the JAK2, MPL and CALR genes in the context of new 2016 WHO classification: prognostic and therapeutic implications. Maedica (Buchar). 2016;11(1):5–25.
   PubMedGoogle Scholar
• Them NC, Kralovics R. Genetic basis of MPN: beyond JAK2-V617F. Curr Hematol Malig Rep. 2013;8(4):299–306.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–3184.
   PubMed Web of Science ®Google Scholar
• Crisa E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691–699.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li C-Y, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973–977.
   PubMed Web of Science ®Google Scholar
• Plo I, Vainchenker W. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma. 2009;9(Suppl 3):S329–S339.
   PubMedGoogle Scholar
• Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550–3560.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Bannister AJ, Göttgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461(7265):819–822.
   PubMed Web of Science ®Google Scholar
• Liu F, Zhao X, Perna F, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011;19(2):283–294.
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680–692.
   PubMed Web of Science ®Google Scholar
• Stanley RF, Steidl U. Molecular mechanism of mutant CALR-mediated transformation. Cancer Discov. 2016;6(4):344–346.
   PubMed Web of Science ®Google Scholar
• Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2013;97(2):183–197.
   PubMed Web of Science ®Google Scholar
• Pecquet C, Staerk J, Chaligné R, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010;115(5):1037–1048.
   PubMed Web of Science ®Google Scholar
• Staerk J, Lacout C, Sato T, et al. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864–1871.
   PubMed Web of Science ®Google Scholar
• Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–2228.
   PubMed Web of Science ®Google Scholar
• McPherson S, McMullin MF, Mills K. Epigenetics in myeloproliferative neoplasms. J Cell Mol Med. 2017;21(9):1660–1667.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–1869.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
   PubMed Web of Science ®Google Scholar
• Kubesova B, Pavlova S, Malcikova J, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2017;1–12.
   PubMedGoogle Scholar
• Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42(9):794–800.
   PubMed Web of Science ®Google Scholar
• Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179–1181.
   PubMed Web of Science ®Google Scholar
• Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer. 2017;17:425–440.
   PubMed Web of Science ®Google Scholar
• Patel U, Luthra R, Medeiros LJ, et al. Diagnostic, prognostic, and predictive utility of recurrent somatic mutations in myeloid neoplasms. Clin Lymphoma Myeloma Leuk. 2017;17:S62–S74.
   Web of Science ®Google Scholar
• Harutyunyan A, Klampfl T, Cazzola M, et al. p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488–490.
   PubMed Web of Science ®Google Scholar
• Girardot M, Pecquet C, Chachoua I, et al. Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene. 2015;34(10):1323–1332.
   PubMed Web of Science ®Google Scholar
• Walerych D, Lisek K, Sommaggio R, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18(8):897–909.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay UK, Cass J, Raptis L, et al. STAT5A is regulated by DNA damage via the tumor suppressor p53. Cytokine. 2016;82:70–79.
   PubMed Web of Science ®Google Scholar
• Berger A, Hoelbl-Kovacic A, Bourgeais J, et al. PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia. 2014;28(3):629–641.
   PubMed Web of Science ®Google Scholar
• Sellar R, Losman JA. Targeting aberrant signaling in myeloid malignancies: promise versus reality. Hematol Oncol Clin North Am. 2017;31(4):565–576.
   PubMed Web of Science ®Google Scholar
• Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756–6767.
   PubMed Web of Science ®Google Scholar
• Armitage J, Tefferi A. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol. 2013;88(10):910–918.
   PubMed Web of Science ®Google Scholar
• Armitage JO. The aggressive peripheral T-cell lymphomas: 2015. Am J Hematol. 2015;90(7):665–673.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Horwitz SM. Current and novel treatment options for peripheral T-cell lymphoma. Clin Adv Hematol Oncol. 2015;13(7):463–466.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin Hematol. 2014;51(1):5–16.
   PubMed Web of Science ®Google Scholar
• Piccaluga P, Tabanelli V, Pileri S. Molecular genetics of peripheral T-cell lymphomas. Int J Hematol. 2014;99(3):219–226.
   PubMed Web of Science ®Google Scholar
• Streubel B, Vinatzer U, Willheim M, et al. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20(2):313–318.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23(3):574–580.
   PubMed Web of Science ®Google Scholar
• Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161(5):1635–1645.
   PubMed Web of Science ®Google Scholar
• Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol. 2001;25(3):285–296.
   PubMed Web of Science ®Google Scholar
• Siu LL, Wong KF, Chan JK, et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol. 1999;155(5):1419–1425.
   PubMed Web of Science ®Google Scholar
• Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol. 2014;51(1):17–24.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–3099.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–2923.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–1036.
   PubMed Web of Science ®Google Scholar
• Laimer D, Dolznig H, Kollmann K, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012;18(11):1699–1704.
   PubMed Web of Science ®Google Scholar
• Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007–3015.
   PubMed Web of Science ®Google Scholar
• Laginestra MA, Piccaluga PP, Fuligni F, et al. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified. Blood Cancer J. 2014;4(11):259.
   PubMedGoogle Scholar
• Crescenzo R, Abate F, Lasorsa E, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516–532.
   PubMed Web of Science ®Google Scholar
• Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741–1752.
   PubMed Web of Science ®Google Scholar
• Wilcox RA. A three signal model of T-cell lymphoma pathogenesis. Am J Hematol. 2016;91(1):113–122.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304–1315.
   PubMed Web of Science ®Google Scholar
• Casulo C, O'Connor O, Shustov A, et al. T-cell lymphoma: recent advances in characterization and new opportunities for treatment. J Natl Cancer Inst. 2017;109(2).
   PubMedGoogle Scholar
• Merkel O, Hamacher F, Sifft E, et al. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther. 2011;10(7):1127–1136.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460–1472.
   PubMed Web of Science ®Google Scholar
• Dierks C, Adrian F, Fisch P, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res. 2010;70(15):6193–6204.
   PubMed Web of Science ®Google Scholar
• Boddicker RL, Kip NS, Xing X, et al. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-kappaB positive feedback loop in peripheral T-cell lymphoma. Blood. 2015;125(20):3118–3127.
   PubMed Web of Science ®Google Scholar
• Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000;289(5488):2350–2354.
   PubMed Web of Science ®Google Scholar
• Schatz JH, Horwitz SM, Teruya-Feldstein J, et al. Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia. 2015;29(1):237–241.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Sahasrabuddhe AA, Rolland DCM, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome. Nat Commun. 2015;6:8470.
   PubMed Web of Science ®Google Scholar
• Lopez C, Bergmann AK, Paul U, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol. 2016;173(2):265–273.
   Web of Science ®Google Scholar
• Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293–1296.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Xi L, Pittaluga S, et al. Frequent STAT5B mutations in [gamma][delta] hepatosplenic T-cell lymphomas. Leukemia. 2014;28(11):2244–2248.
   PubMed Web of Science ®Google Scholar
• Rajala HLM, Eldfors S, Kuusanmäki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121(22):4541–4550.
   PubMed Web of Science ®Google Scholar
• Bandapalli OR, Schuessele S, Kunz JB, et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica. 2014;99(10): e188–e192.
   Web of Science ®Google Scholar
• Kontro M, Kuusanmäki H, Eldfors S, et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(8):1738–1742.
   PubMed Web of Science ®Google Scholar
• Küçük C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun. 2015;6(6025).
   PubMedGoogle Scholar
• Stengel A, Kern W, Zenger M, et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker. Genes Chromosomes Cancer. 2016;55(1):82–94.
   PubMed Web of Science ®Google Scholar
• Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008;68(10):3785–3794.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Rossi M, Agostinelli C, et al. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. Leukemia. 2014;28(8):1687–1697.
   PubMed Web of Science ®Google Scholar
• Kopp KL, Ralfkiaer U, Gjerdrum LMR, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013;12(12):1939–1947.
   PubMed Web of Science ®Google Scholar
• Sibbesen NA, Kopp KL, Litvinov IV, et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-cell lymphoma. Oncotarget. 2015;6(24):20555–20569.
   PubMed Web of Science ®Google Scholar
• Lauenborg B, Christensen L, Ralfkiaer U, et al. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma. Oncotarget. 2015;6(17):15235–15249.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang HY, Wei F, et al. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J Immunol. 2014;192(6):2913–2919.
   PubMed Web of Science ®Google Scholar
• Litvinov IV, Netchiporouk E, Cordeiro B, et al. The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL). Clin Cancer Res. 2015;21(12):2820–2829.
   PubMed Web of Science ®Google Scholar
• Goyama S, Kitamura T. Epigenetics in normal and malignant hematopoiesis: an overview and update 2017. Cancer Sci. 2017;108(4):553–562.
   PubMed Web of Science ®Google Scholar
• Ondrejka SL, Hsi ED. T-cell lymphomas: updates in biology and diagnosis. Surg Pathol Clin. 2016;9(1):131–141.
   PubMedGoogle Scholar
• Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371–375.
   PubMed Web of Science ®Google Scholar
• Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166–170.
   PubMed Web of Science ®Google Scholar
• Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171–175.
   PubMed Web of Science ®Google Scholar
• Lemonnier F, Couronné L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466–1469.
   PubMed Web of Science ®Google Scholar
• Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95–96.
   PubMed Web of Science ®Google Scholar
• Hildyard CAT, Shiekh S, Browning JAB, et al. Toward a biology-driven treatment strategy for peripheral T-cell lymphoma. Clin Med Insights. 2017;10( 10.1177_1179545X17705863.xml):1179545X17705863.
   Google Scholar
• Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25–38.
   PubMed Web of Science ®Google Scholar
• Muto H, Sakata-Yanagimoto M, Nagae G, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4:e264.
   PubMed Web of Science ®Google Scholar
• Karimi MM, Goyal P, Maksakova IA, et al. DNA methylation and SETDB1/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. Cell Stem Cell. 2011;8(6):676–687.
   PubMed Web of Science ®Google Scholar
• Chang Y, Sun L, Kokura K, et al. MPP8 mediates the interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase GLP/G9a. Nat Commun. 2011;2:533.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Nishioka C, Ikezoe T, et al. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells. Leuk Res. 2015;39(8):897–905.
   PubMed Web of Science ®Google Scholar
• Rush M, Appanah R, Lee S, et al. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Epigenetics. 2009;4(6):404–414.
   PubMed Web of Science ®Google Scholar
• Holz-Schietinger C, Matje DM, Reich NO. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem. 2012;287(37):30941–30951.
   PubMed Web of Science ®Google Scholar
• Haney SL, Upchurch GM, Opavska J, et al. Dnmt3a is a haploinsufficient tumor suppressor in CD8+ peripheral T cell lymphoma. PLoS Genet. 2016;12(9):e1006334.
   PubMed Web of Science ®Google Scholar
• Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472–1478.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901–1903.
   PubMed Web of Science ®Google Scholar
• Lemonnier F, Cairns RA, Inoue S, et al. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci USA. 2016;113(52):15084–15089.
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle V, Hamoudi R, Matutes E, et al. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. Br J Haematol. 2000;110(1):180–187.
   PubMed Web of Science ®Google Scholar
• Cui Y-X, Kerby A, McDuff FKE, et al. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood. 2009;113(21):5217–5227.
   PubMed Web of Science ®Google Scholar
• Matei IR, Guidos CJ, Danska JS. ATM-dependent DNA damage surveillance in T-cell development and leukemogenesis: the DSB connection. Immunol Rev. 2006;209:142–158.
   PubMed Web of Science ®Google Scholar
• Bourgeais J, Ishac N, Medrzycki M, et al. Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. Oncotarget. 2016.
   PubMed Web of Science ®Google Scholar
• Cholez E, Debuysscher V, Bourgeais J, et al. Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells. Leukemia. 2012;26(11):2390–2397.
   PubMed Web of Science ®Google Scholar
• Jayavelu AK, Moloney JN, Böhmer F-D, et al. NOX-driven ROS formation in cell transformation of FLT3-ITD positive AML. Exp Hematol. 2016;44(12):1113–1122.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raje V, Yakovlev VA, et al. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J Biol Chem. 2013;288(43):31280–31288.
   PubMed Web of Science ®Google Scholar
• Themanns M, Mueller KM, Kessler SM, et al. Hepatic deletion of Janus Kinase 2 counteracts oxidative stress in mice. Sci Rep. 2016;6:34719.
   PubMed Web of Science ®Google Scholar
• Friedbichler K, Themanns M, Mueller KM, et al. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology. 2012;55(3):941–952.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Dasgupta Y, Ren S-Y, et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 2011;118(4):1062–1068.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8(4):795–806.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Kontani K, Enami T, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood. 2016;127(5):596–604.
   PubMed Web of Science ®Google Scholar
• Hanna S, El-Sibai M. Signaling networks of Rho GTPases in cell motility. Cell Signal. 2013;25(10):1955–1961.
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr. STATs and gene regulation. Science. 1997;277(5332):1630–1635.
   PubMed Web of Science ®Google Scholar
• Kucuk C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015;6:6025.
   PubMed Web of Science ®Google Scholar
• Levy DE, Inghirami G. STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA. 2006;103(27):10151–10152.
   PubMed Web of Science ®Google Scholar
• Andersson E, Kuusanmäki H, Bortoluzzi S, et al. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia. 2016;30(5):1204–1208.
   PubMed Web of Science ®Google Scholar
• Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997;8(12):1267–1276.
   PubMedGoogle Scholar
• Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608–1619.
   PubMed Web of Science ®Google Scholar
• Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13(2):211–217.
   PubMed Web of Science ®Google Scholar
• Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276(48):45443–45455.
   PubMed Web of Science ®Google Scholar
• Timofeeva OA, Gaponenko V, Lockett SJ, et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol. 2007;2(12):799–809.
   PubMed Web of Science ®Google Scholar
• Huang W, Dong Z, Wang F, et al. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem Biol. 2014;9(5):1188–1196.
   PubMed Web of Science ®Google Scholar
• Page BDG, Khoury H, Laister RC, et al. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem. 2012;55(3):1047–1055.
   PubMed Web of Science ®Google Scholar
• Fletcher S, Drewry JA, Shahani VM, et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol. 2009;87(6):825–833.
   PubMed Web of Science ®Google Scholar
• Haftchenary S, Avadisian M, Gunning PT. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anticancer Drugs. 2011;22(2):115–127.
   PubMed Web of Science ®Google Scholar
• Auzenne EJ, Klostergaard J, Mandal PK, et al. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol. 2012;10(2):155–162.
   PubMedGoogle Scholar
• Chen J, Bai L, Bernard D, et al. structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACS Med Chem Lett. 2010;1(2):85–89.
   PubMed Web of Science ®Google Scholar
• Coleman DRT, Ren Z, Mandal PK, et al. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J Med Chem. 2005;48(21):6661–6670.
   PubMed Web of Science ®Google Scholar
• Fossey SL, Bear MD, Lin J, et al. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer. 2011;11:112.
   PubMed Web of Science ®Google Scholar
• Gunning PT, Katt WP, Glenn M, et al. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett. 2007;17(7):1875–1878.
   PubMed Web of Science ®Google Scholar
• Hao W, Hu Y, Niu C, et al. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg Med Chem Lett. 2008;18(18):4988–4992.
   PubMed Web of Science ®Google Scholar
• Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010;70(6):2445–2454.
   PubMed Web of Science ®Google Scholar
• Onimoe G-I, Liu A, Lin L, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012;30(3):916–926.
   PubMed Web of Science ®Google Scholar
• Schust J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13(11):1235–1242.
   PubMed Web of Science ®Google Scholar
• Siddiquee KAZ, Gunning PT, Glenn M, et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol. 2007;2(12):787–798.
   PubMed Web of Science ®Google Scholar
• Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA. 2005;102(13):4700–4705.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yue P, Page BDG, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA. 2012;109(24):9623–9628.
   PubMed Web of Science ®Google Scholar
• Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004;3(3):261–269.
   PubMed Web of Science ®Google Scholar
• Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421–3429.
   PubMed Web of Science ®Google Scholar
• Müller J, Sperl B, Reindl W, et al. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem. 2008;9(5):723–727.
   PubMed Web of Science ®Google Scholar
• Nam S, Scuto A, Yang F, et al. Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol. 2012;6(3):276–283.
   PubMed Web of Science ®Google Scholar
• Cumaraswamy AA, Lewis AM, Geletu M, et al. Nanomolar-potency small molecule inhibitor of STAT5 protein. ACS Med Chem Lett. 2014;5(11):1202–1206.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Zhuang G, Cao Y, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26(2):207–221.
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Schneeweiss M, Eisenwort G, et al. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017;102(9):1519–1529.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017;129(6):693–703.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Komrokji RS. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 2015;11(20):2819–2830.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Talpaz M, Ritchie E, et al. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017;31(2):393–402.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069–2076.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166–173.
   PubMed Web of Science ®Google Scholar
• Barbarotta L, Hurley K. Romidepsin for the treatment of peripheral T-cell lymphoma. J Adv Pract Oncol. 2015;6(1):22–36.
   PubMedGoogle Scholar
• Sawas A, Radeski D, O’Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015;6(4):202–208.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–2499.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–636.
   PubMed Web of Science ®Google Scholar
• Lu X, Ning Z, Li Z, et al. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis Res. 2016;5(3):185–191.
   PubMed Web of Science ®Google Scholar
• Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.
   PubMedGoogle Scholar
• Bhagwat N, Koppikar P, Keller M, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014;123:2075–2083.
   PubMed Web of Science ®Google Scholar
• Daver N, Verstovsek S. Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma. 2015;56(2):279–280.
   PubMed Web of Science ®Google Scholar
• Shen J, Vakifahmetoglu H, Stridh H, et al. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene. 2008;27(51):6571–6580.
   PubMed Web of Science ®Google Scholar
• Wang T, Lee K, Rehman A, et al. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Biochem Biophys Res Commun. 2007;352(1):203–212.
   PubMed Web of Science ®Google Scholar
• Lu M, Wang X, Li Y, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120(15):3098–3105.
   PubMed Web of Science ®Google Scholar